SAN DIEGO — Daratumumab monotherapy significantly delayed progression of high-risk smoldering multiple myeloma to active multiple myeloma compared with active monitoring, according to results of the randomized phase 3 AQUILA study.
Daratumumab (Darzalex, Janssen) reduced risk for progression or death by 51%, findings presented at ASH Annual Meeting and Exposition showed. Less than 6% of patients had to stop treatment due to toxicities.
“This study may be practice changing as far as patients with smoldering myeloma and high-risk features are concerned,” Meletios A. Dimopoulos,